|
|
| | rotigaptide Basic information |
| Product Name: | rotigaptide | | Synonyms: | rotigaptide;ZP123;Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl-;Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2;(2R,4S)-1-(Acetyl-D-tyrosyl-D-prolyl)-N-(2-(((R)-1-((2-amino-2-oxoethyl)amino)-1-oxopropan-2-yl)amino)-2-oxoethyl)-4-hydroxypyrrolidine-2-carboxamide | | CAS: | 355151-12-1 | | MF: | C28H39N7O9 | | MW: | 617.65 | | EINECS: | | | Product Categories: | | | Mol File: | 355151-12-1.mol |  |
| | rotigaptide Chemical Properties |
| Boiling point | 1187.3±65.0 °C(Predicted) | | density | 1.396±0.06 g/cm3(Predicted) | | pka | 9.84±0.15(Predicted) | | form | Solid | | color | White to light yellow |
| | rotigaptide Usage And Synthesis |
| Uses | Treatment of ventricular tachycardia or ventricular fibrillation. | | Uses | Rotigaptide is a potent antiarrhythmic peptide (AAP) with improved stability and has the potential for the investigation of cardiac arrhythmias-specificallyatrial fibrillation. Rotigaptide protects myocardium and arterial vasculature from ischemia reperfusion injury | | in vivo | Rotigaptide (intravenous administration; 300 mg/kg; single dose) treatment in mice and rats does not result in toxicity in either species.In escalating dose studies, Rotigaptide (continuous intravenous infusion; 5-14 days) in rats (100 mg/kg) and dogs (10 mg/kg) are well tolerated and produces no compound-related effects or histological toxicological findings[3]. |
| | rotigaptide Preparation Products And Raw materials |
|